Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WIC reauthorization

This article was originally published in The Tan Sheet

Executive Summary

The Department of Agriculture requests comments on its Women, Infants and Children program as it prepares to work with Congress on the reauthorization of its supplemental nutrition programs in 2009. In a May 20 Federal Register notice, USDA asks for comments, which are due by Oct. 15, to address three themes it proposed to frame reauthorization of WIC and its Child Nutrition Programs: strengthening program management and improving nutrition services, ensuring all eligible persons have access to benefits and advancing technology and innovation. The Natural Products Association has lobbied for WIC coverage to include vitamin D supplementation, a change the USDA did not include in a December 2007 interim rule to revise the program (1"The Tan Sheet" Jan. 14, 2008, p. 10)...

You may also be interested in...



Adding Supplements to Federal Support Programs Needs Industry Push – NPA

A proposal to exclude vitamin D supplementation from a federal nutrition program and continued apathy in Congress toward adding multivitamins and dietary supplements to the food stamp program are signals it is time for the industry to push harder for change, a Natural Products Association executive says

Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.

Intuitive Exceeds Expectations In Q1 As Da Vinci Sales And Surgeries Recover

The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.

Topics

UsernamePublicRestriction

Register

PS101732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel